Methylprednisolone pulse therapy for critically ill patients with COVID-19: a cohort study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background The guidelines recommend the use of dexamethasone 6 mg or an equivalent dose in patients with coronavirus disease 2019 (COVID-19) who require supplemental oxygen. Given that the severity of COVID-19 varies, we investigated the effect of a pulse dose of corticosteroids on the clinical course of critically ill patients with COVID-19. Methods This single-center, retrospective cohort study was conducted between September and December 2021, which was when the Delta variant of the COVID-19 virus was predominant. We evaluated the mortality and oxygenation of severe to critical COVID-19 cases between groups that received dexamethasone 6 mg for 10 days (control group) and methylprednisolone 250 mg/day for 3 days (pulse group). Results Among 44 patients, 14 and 30 patients were treated with control steroids and pulse steroids, respectively. There was no difference in disease severity, time from COVID-19 diagnosis to steroid administration, or use of remdesivir or antibacterial agents between the two groups. The pulse steroid group showed a significant improvement in oxygenation before and after steroid treatment (P<0.001) compared with the control steroid group (P=0.196). There was no difference in in-hospital mortality (P=0.186); however, the pulse steroid group had a lower mortality rate (23.3%) than the control steroid group (42.9%). There was a significant difference in the length of hospital stay between both two groups (P=0.039). Conclusions Pulse steroids showed no mortality benefit but were associated with oxygenation improvement and shorter hospital stay than control steroids. Hyperglycemia should be carefully monitored with pulse steroids.
Abstract
Background The guidelines recommend the use of dexamethasone 6 mg or an equivalent dose in patients with coronavirus disease 2019 (COVID-19) who require supplemental oxygen. Given that the severity of COVID-19 varies, we investigated the effect of a pulse dose of corticosteroids on the clinical course of critically ill patients with COVID-19. Methods This single-center, retrospective cohort study was conducted between September and December 2021, which was when the Delta variant of the COVID-19 virus was predominant. We evaluated the mortality and oxygenation of severe to critical COVID-19 cases between groups that received dexamethasone 6 mg for 10 days (control group) and methylprednisolone 250 mg/day for 3 days (pulse group). Results Among 44 patients, 14 and 30 patients were treated with control steroids and pulse steroids, respectively. There was no difference in disease severity, time from COVID-19 diagnosis to steroid administration, or use of remdesivir or antibacterial agents between the two groups. The pulse steroid group showed a significant improvement in oxygenation before and after steroid treatment (P<0.001) compared with the control steroid group (P=0.196). There was no difference in in-hospital mortality (P=0.186); however, the pulse steroid group had a lower mortality rate (23.3%) than the control steroid group (42.9%). There was a significant difference in the length of hospital stay between both two groups (P=0.039). Conclusions Pulse steroids showed no mortality benefit but were associated with oxygenation improvement and shorter hospital stay than control steroids. Hyperglycemia should be carefully monitored with pulse steroids.
참고문헌 (35)
- Gibson PG, "COVID-19 acute respiratory distress syndrome(ARDS) : clinical features and differences from typical pre-COVID-19 ARDS", Med J Aust, 213, pp.54~56 (2020)
- Gattinoni L, "COVID-19 pneumonia : pathophysiology and management", Eur Respir Rev, 30, pp.210138~ (2021)
- England JT, "Weathering the COVID-19 storm : lessons from hematologic cytokine syndromes", Blood Rev, 45, pp.100707~ (2021)
- Alhazzani W, "Surviving Sepsis Campaign : guidelines on the management of critically ill adults with coronavirus disease 2019(COVID-19)", Intensive Care Med, 46, pp.854~887 (2020)
- Alhazzani W, "Surviving Sepsis Campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update", Crit Care Med, 49, pp.e219~e234 (2019)
- RECOVERY Collaborative Group, "Dexamethasone in hospitalized patients with COVID-19", N Engl J Med, 384, pp.693~704 (2021)
- Dequin PF, "Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19 : a randomized clinical trial", JAMA, 324, pp.1298~1306 (2020)
- Angus DC, "The REMAP-CAP(Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia)Study : rationale and design", Ann Am Thorac Soc, 17, pp.879~891 (2020)
- Jeronimo CM, "Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase IIb, placebo-controlled trial", Clin Infect Dis, 72, pp.e373~e381 (2019)
- De Backer D, "Corticosteroids in severe COVID-19 : a critical view of the evidence", Crit Care, 24, pp.627~ (2020)
- WHO Rapid Evidence Appraisal for COVID-19 Therapies(REACT)Working Group, "Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19 : a meta-analysis", JAMA, 324, pp.1330~1341 (2020)
- Jose RJ, "COVID-19 cytokine storm : the interplay between inflammation and coagulation", Lancet Respir Med, 8, pp.e46~7 (2020)
- Umberto Meduri G, "Pathophysiology of acute respiratory distress syndrome : glucocorticoid receptor-mediated regulation of inflammation and response to prolonged glucocorticoid treatment", Presse Med, 40(12 Pt 2), pp.e543~60 (2011)
- Jang J, "One-year report of COVID-19 outbreak in the Republic of Korea, January-December 2021", Public Health Wkly Rep, 15, pp.225~234 (2022)
- Meikle AW, "Potency and duration of action of glucocorticoids : effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function", Am J Med, 63, pp.200~207 (1977)
- ARDS Definition Task Force, "Acute respiratory distress syndrome : the Berlin Definition", JAMA, 307, pp.2526~2533 (2012)
- Warren MA, "Severity scoring of lung oedema on the chest radiograph is associated with clinical outcomes in ARDS", Thorax, 73, pp.840~846 (2018)
- Hasan SS, "Does methylprednisolone reduce the mortality risk in hospitalized COVID-19 patients? : a meta-analysis of randomized control trials", Expert Rev Respir Med, 15, pp.1049~1055 (2021)
- Wagner C, "Systemic corticosteroids for the treatment of COVID-19", Cochrane Database Syst Rev, 8, pp.CD014963~ (2021)
- Villar J, "Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19 : study protocol for a randomized controlled superiority trial", Trials, 21, pp.717~ (2020)
- Tomazini BM, "Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19 : the CoDEX randomized clinical trial", JAMA, 324, pp.1307~1316 (2020)
- COVID STEROID 2 Trial Group, "Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia : the COVID STEROID 2 randomized trial", JAMA, 326, pp.1807~1817 (2021)
- Monedero P, "Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19 : a cohort study", Crit Care, 25, pp.2~ (2021)
- Edalatifard M, "Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients : results from a randomised controlled clinical trial", Eur Respir J, 56, pp.2002808~ (2020)
- Chaudhuri D, "Corticosteroids in COVID-19 and non-COVID-19 ARDS : a systematic review and meta-analysis", Intensive Care Med, 47, pp.521~537 (2021)
- Buicu AL, "Systemic inflammation and COVID-19 mortality in patients with major noncommunicable diseases : chronic coronary syndromes, diabetes and obesity", J Clin Med, 10, pp.1545~ (2021)
- Meduri GU, "Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome : a randomized controlled trial", JAMA, 280, pp.159~165 (1998)
- Meduri GU, "Methylprednisolone infusion in early severe ARDS : results of a randomized controlled trial", Chest, 131, pp.954~963 (2007)
- Steinberg KP, "Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome", N Engl J Med, 354, pp.1671~1684 (2006)
- Confalonieri M, "Hydrocortisone infusion for severe community-acquired pneumonia : a preliminary randomized study", Am J Respir Crit Care Med, 171, pp.242~248 (2005)
- Xie J, "Association between hypoxemia and mortality in patients with COVID-19", Mayo Clin Proc, 95, pp.1138~1147 (2020)
- Vecchié A, "High-dose dexamethasone treatment for COVID-19 severe acute respiratory distress syndrome : a retrospective study", Intern Emerg Med, 16, pp.1913~1919 (2021)
- Muramatsu KI, "Severe COVID-19 pneumonia treated by intensive immune suppression therapy with a combination of steroid pulse and tocilizumab followed by a tapering dose of steroid therapy during the Delta(B. 1. 617. 2)variant outbreak : a successfully treated case", Cureus, 13, pp.e19340~ (2021)
- Mammen MJ, "Corticosteroids for patients with acute respiratory distress syndrome : a systematic review and meta-analysis of randomized trials", Pol Arch Intern Med, 130, pp.276~286 (2020)
- Pinzón MA, "Dexamethasone vs methylprednisolone high dose for COVID-19 pneumonia", PLoS One, 16, pp.e0252057~ (2021)